MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463267 | Name: TB500 free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TB-500 is a synthetic version of an active region of thymosin β4. TB 500 promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation. A veterinary preparation known as TB-500 and containing a synthetic version of the naturally occurring peptide LKKTETQ has emerged. The peptide segment (17)LKKTETQ(23) is the active site within the protein thymosin β(4) responsible for actin binding, cell migration and wound healing. The key ingredient of TB-500 is the peptide LKKTETQ with artificial acetylation of the N-terminus. TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation.

Chemical Structure

TB500 free base
TB500 free base
CAS#885340-08-9 (free base)

Theoretical Analysis

MedKoo Cat#: 463267

Name: TB500 free base

CAS#: 885340-08-9 (free base)

Chemical Formula: C38H68N10O14

Exact Mass: 888.4916

Molecular Weight: 889.02

Elemental Analysis: C, 51.34; H, 7.71; N, 15.76; O, 25.19

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
TB500 TFA 885340-08-9 (free base) 75591-33-4
Synonym
TB500; TB 500; TB-500; L-Glutamine, N-acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-α-glutamyl-L-threonyl-;
IUPAC/Chemical Name
(2S,5S,8S,11S,14S,17S,20S)-2-(3-amino-3-oxopropyl)-14,17-bis(4-aminobutyl)-8-(2-carboxyethyl)-5,11-bis((R)-1-hydroxyethyl)-20-isobutyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatricosanoic acid
InChi Key
ADKDNDYYIZUVCZ-ZQNQAVPYSA-N
InChi Code
InChI=1S/C38H68N10O14/c1-19(2)18-27(42-22(5)51)35(58)44-23(10-6-8-16-39)32(55)43-24(11-7-9-17-40)33(56)47-30(20(3)49)36(59)45-25(13-15-29(53)54)34(57)48-31(21(4)50)37(60)46-26(38(61)62)12-14-28(41)52/h19-21,23-27,30-31,49-50H,6-18,39-40H2,1-5H3,(H2,41,52)(H,42,51)(H,43,55)(H,44,58)(H,45,59)(H,46,60)(H,47,56)(H,48,57)(H,53,54)(H,61,62)/t20-,21-,23+,24+,25+,26+,27+,30+,31+/m1/s1
SMILES Code
O=C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 889.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 1;1235:124033. doi: 10.1016/j.jchromb.2024.124033. Epub 2024 Feb 7. PMID: 38382158. 2: Delcourt V, Garcia P, Chabot B, Barnabé A, Bouscarel M, Loup B, Popot MA, Bailly-Chouriberry L. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023 Apr;15(4):458-464. doi: 10.1002/dta.3421. Epub 2022 Dec 23. PMID: 36482504. 3: Jing J, Tian T, Wang Y, Xu X, Shan Y. Multi-analyte screening of small peptides by alkaline pre-activated solid phase extraction coupled with liquid chromatography-high resolution mass spectrometry in doping controls. J Chromatogr A. 2022 Aug 2;1676:463272. doi: 10.1016/j.chroma.2022.463272. Epub 2022 Jun 22. PMID: 35802965. 4: Judák P, Van Eenoo P, Deventer K. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Anal Biochem. 2017 Nov 15;537:69-71. doi: 10.1016/j.ab.2017.09.003. Epub 2017 Sep 5. PMID: 28887173. 5: Zvereva I, Semenistaya E, Krotov G, Rodchenkov G. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. J Proteomics. 2016 Oct 21;149:85-97. doi: 10.1016/j.jprot.2016.08.016. Epub 2016 Aug 26. PMID: 27569051. 6: Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W, Thevis M. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci. 2016 Jan;39(2):333-41. doi: 10.1002/jssc.201501060. Epub 2015 Dec 15. PMID: 26578461. 7: Semenistaya E, Zvereva I, Krotov G, Rodchenkov G. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. Drug Test Anal. 2016 Sep;8(9):940-9. doi: 10.1002/dta.1890. Epub 2015 Oct 16. PMID: 26472487. 8: Esposito S, Deventer K, Geldof L, Van Eenoo P. In vitro models for metabolic studies of small peptide hormones in sport drug testing. J Pept Sci. 2015 Jan;21(1):1-9. doi: 10.1002/psc.2710. Epub 2014 Dec 3. PMID: 25469748. 9: Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Rev Proteomics. 2014 Dec;11(6):663-73. doi: 10.1586/14789450.2014.965159. Epub 2014 Nov 8. PMID: 25382550. 10: Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014 Dec;101:66-83. doi: 10.1016/j.jpba.2014.05.020. Epub 2014 May 23. PMID: 24906629. 11: Kwok WH, Ho EN, Lau MY, Leung GN, Wong AS, Wan TS. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2013 Mar;405(8):2595-606. doi: 10.1007/s00216-012-6697-9. Epub 2013 Jan 15. PMID: 23318763. 12: Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23;1265:57-69. doi: 10.1016/j.chroma.2012.09.043. Epub 2012 Sep 23. PMID: 23084823. 13: Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012 Sep;4(9):733-8. doi: 10.1002/dta.1402. Epub 2012 Sep 7. PMID: 22962027.